Drug Profile
Bevufenogene nofeparvovec - Q32 Bio
Alternative Names: AAVHSC15-PAH; HMI-102Latest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Homology Medicines
- Developer Q32 Bio
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Phenylketonuria
Most Recent Events
- 25 Mar 2024 Q32 Bio has merged with Homology Medicines to form Q32 Bio
- 24 Aug 2023 Homology Medicines terminates a phase I/II pheNIX trial in Phenylketonuria in USA (IV) due to discontinuation of the programme (NCT03952156)
- 27 Jul 2023 Bevufenogene nofeparvovec - Homology Medicines is available for licensing as of 27 Jul 2023. https://www.homologymedicines.com/pipeline/